Clinical trials: Thymoma and Thymic Carcinoma
Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin
An International Study on Pediatric Patients With Rare Tumors.
The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.
- Conditions
- Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin, Gastrointestinal Stromal Tumor (GIST), Adrenocortical Tumor
- Trial name
- PARTNER (NCT07072143)
- Where
- Italy
- Volunteers
- 6,250 people
- Sponsor
- Azienda Ospedaliera di Padova
Unresectable Thymic Carcinoma
A Phase II, Investigator-Initiated Exploratory Study of Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas
This is a non-randomized, open-label, investigator-initiated phase II clinical trial designed to evaluate the efficacy and safety of sacituzumab tirumotecan (hereafter referred to as sac-TMT) in patients with unresectable thymic…
- Trial name
- XANTHOS (NCT07750353)
- Testing
- Sacituzumab Tirumotecan (Sac-TMT)
- Where
- 3 sites in Japan
- Volunteers
- 35 people
- Sponsor
- National Cancer Center, Japan
Thymoma, Thymic Carcinoma
A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy
Background: Thymoma and thymic carcinoma are cancers originating in the thymus gland. Platinum-based chemotherapy is standard treatment for them.
- Trial name
- NCT03076554
- Testing
- Avelumab
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Thymoma, Thymic Carcinoma
Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma
To study the efficacy of Alimta as a single agent in thymic cancers
- Trial name
- NCT00198133
- Testing
- Premetrexed (Alimta)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Patrick Joseph Loehrer Sr.
Carcinoma, Thymic
A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma
This is a phase II, open-label, single-arm, multicenter study of the efficacy and safety of atezolizumab treatment in participants with advanced thymic carcinoma who failed prior systemic therapy.
- Trial name
- NCT04321330
- Testing
- Atezolizumab
- Where
- 10 sites in China
- Volunteers
- 34 people
- Sponsor
- Hoffmann-La Roche
Thymic Epithelial Tumor, Thymic Carcinoma
Molecular Analysis and Treatment Options of Thymic Malignancies
Thymic malignancies are the most common tumors of the anterior mediastinum, though surgery and radiation often effectively treat thymic carcinomas, a minority continue to progress and eventually lead to death.
- Conditions
- Thymic Epithelial Tumor, Thymic Carcinoma, Thymic Cancer
- Trial name
- NCT05667948
- Testing
- Chemotherapy
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai Chest Hospital
Lung Cancer, Malignant Mesothelioma
Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer.
- Conditions
- Lung Cancer, Malignant Mesothelioma, Metastatic Cancer, Thymoma and Thymic Carcinoma
- Trial name
- NCT00024076
- Testing
- radiofrequency ablation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Thymus Carcinoma
Ivonescimab for the Treatment of Thymic Cancer
This phase II trial tests how well ivonescimab works in treating patients with thymic carcinoma. Immunotherapy with monoclonal antibodies, such as ivonescimab, may help the body's immune system attack the cancer, and may…
- Trial name
- NCT06980077
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Thymoma, Thymus Neoplasms
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
Background: Sunitinib is drug that is approved for treating various types of cancers, including kidney cancers. However, it has not been approved to treat cancers of the thymus.
- Trial name
- NCT01621568
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Thymic Epithelial Tumor, Thymic Carcinoma
Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors
Thymic epithelial tumors are rare neoplasms in the anterior mediastinum. The cornerstone of the treatment is surgical resection.
- Conditions
- Thymic Epithelial Tumor, Thymic Carcinoma, Thymoma, Thymoma and Thymic Carcinoma
- Trial name
- INTHYM (NCT06301945)
- Testing
- Artificial Intelligence Diagnostics, Recurrence Prediction Tool
- Where
- Netherlands
- Volunteers
- 1,020 people
- Sponsor
- Erasmus Medical Center
Pleural Metastases, Breast Cancer
Heated Chemotherapy for Cancers That Have Spread to the Chest Cavity
Cancers that have spread to the inner lining of the chest are classified as Stage IV and bear a poor prognosis. Surgery is rarely an option, with palliative chemotherapy and/or radiation therapy the only treatment options.
- Conditions
- Pleural Metastases, Breast Cancer, Colon Cancer, Ovarian Cancer
- Trial name
- NCT01163552
- Testing
- Surgical debulking and Intrathoracic Hyperthermic Chemotherapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- St. Luke's-Roosevelt Hospital Center
Thymic Cancer, Thymoma
A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer
The purpose of this study is to determine the rate of response with the combination of erlotinib and bevacizumab in previously treated patients with thymoma or thymic carcinoma, and to determine potential molecular markers that…
- Trial name
- NCT00369889
- Testing
- bevacizumab, Erlotinib
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Indiana University
Pancreas Cancer, Ovarian Cancer
Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
This is a single arm, single-stage, phase II trial to evaluate the activity of Regorafenib in patients with metastatic solid tumors (pancreatic cancer, ovarian cancer, melanoma, sarcoma, thymoma (type B2 - B3) and thymic…
- Conditions
- Pancreas Cancer, Ovarian Cancer, Melanoma, Sarcoma
- Trial name
- RESOUND (NCT02307500)
- Testing
- Regorafenib
- Where
- Italy
- Volunteers
- 82 people
- Sponsor
- Istituto Clinico Humanitas
Thymoma and Thymic Carcinoma
Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma
This is an investigational, single arm study.
- Trial name
- NCT04554524
- Testing
- Chemotherapy+Pembrolizumab.
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tang-Du Hospital
Life Threatening Diseases
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of…
- Trial name
- NCT00154388
- Testing
- Imatinib mesylate
- Volunteers
- 185 people
- Sponsor
- Novartis Pharmaceuticals
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Lung Cancer, Esophageal Cancer
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
Background: Certain types of lung, esophageal, or thymic cancers and mesotheliomas have specific antigens (protein molecules) on their surfaces.
- Conditions
- Lung Cancer, Esophageal Cancer, Malignant Pleural Mesothelioma, Sarcoma
- Trial name
- NCT01143545
- Testing
- Allogeneic Tumor Cell Vaccine (K562), Celecoxib, cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Thymoma and Thymic Carcinoma, Thymoma
Hypofractionated Radiotherapy for Thymic Epithelial Tumors
The goal of this clinical trial is to learn if hypofractionated radiotherapy works to shorten the treatment time without increasing the side effects in patients of thymic epithelial tumors.
- Conditions
- Thymoma and Thymic Carcinoma, Thymoma, Thymic Cancer, Thymic Epithelial Tumor
- Trial name
- NCT06692062
- Testing
- Hypofractionated Radiation Therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Rongrong Zhou
B2 Thymoma, Thymic Carcinoma
Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
This Phase 1/2 study evaluates the safety, tolerability, and preliminary efficacy of target-selected CAR-natural killer (CAR-NK) cells in adults with relapsed or refractory B2 thymoma or thymic carcinoma.
- Trial name
- SELECT-NK-THYM (NCT07598955)
- Testing
- Cyclophosphamide, Fludarabine, EB-CAR30-NK
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Beijing Biotech
Thymic Epithelial Tumor, Recurrent Thymoma
Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma
Background: Thymoma and thymic carcinoma are diseases of the thymus. Platinum-based chemotherapy is the standard treatment for these diseases. But in many cases, the disease returns after treatment.
- Conditions
- Thymic Epithelial Tumor, Recurrent Thymoma, Thymic Cancer
- Trial name
- NCT04417660
- Testing
- M7824
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)